Galderma News
Most Popular Galderma Story
MediGene sells European rights to Oracea
MediGene has sold the European rights to Oracea for rosacea to Galderma Laboratories for €8 million upfront and up to €32 million in total based on certain commercialization milestones. Read more...
Latest Headlines
- July 31, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


